Research

 

60 years of Nordic Collaboration to Advance the Prevention

 

and Treatment of Cancer 

The Nordic Cancer Union is a collaborative body for cancer societies in the Nordic countries. The aims of NCU are:

 

  • Improved  knowledge and understanding of cancer
  • More effective prevention of cancer
  • Better results from cancer treatment and rehabilitation
  • Enhanced application of cancer treatment in the Nordic countries

 

To achieve these aims, NCU grants one million euro each year to strategic projects and collaborative cancer research within the Nordic countries.

Apply for a grant from NCU »

 

Read NCU's Annual Report »
 

Cancer in the Nordic countries 

 

Visit the NORDCAN-project for statisitcs on the incidence, mortality and prevalence of 41 major cancers in the Nordic countries. The project receives funding from NCU.

 

Recently published research supported by NCU include:
 

Immature cells are found in spinal fluid in some cases of childhood acute lymphoblastic leukemia by PK Kjeld Schmiegelow.

In Central nervous system (CNS) involvement is associated with relapse in childhood acute lymphoblastic leukemia (ALL) and is a diagnostic challenge. “In a Nordic/Baltic prospective study, we assessed centralized flow cytometry (FCM) of locally fixed cerebrospinal fluid (CSF) samples versus local conventional cytospin-based cytology (CC) for detecting leukemic cells and evaluating kinetics of elimination of leukemic cells in CSF.”

The study included samples from several countries and the study opened in Denmark, Finland, and Lithuania in 2012 and in Norway and Sweden in 2013. The authors state: “Longer follow-up is needed to clarify whether FCM positivity has prognostic significance and is an indicator for intensified CNS-directed therapy.”

 

Human papillomavirus (HPV) vaccine has acceptable safety in boys 12-15 years by PI Joakim Dillner.

The HPV vaccine proctects against cervical cancer, anal cancer, vaginal cancer and vulvar cancer. Active monitoring of Finnish boys and girls recruited from 1992-1995 birth cohorts to look at the safety of HPV vaccination in boys

The authors state, “Active monitoring showed that the HPV-16/18 vaccine has acceptable safety and reactogenicity in boys.”

See also the latest published papers from 2015.

 

 

NCU Secretariat

 

c/o The Icelandic Cancer Society

 

Skógarhlíð 8

105 Reykjavík

Iceland

 

Tel.: +354 540 1900 

E-mail: krabb@krabb.is

 

Contact person: Ragnheiður Haraldsdóttir

E-mail: ragnheidur@krabb.is
 

Web: www.krabb.is

NCU Research Administration
 

c/o Norwegian Cancer Society (Kreftforeningen)

 

Postboks 4 Sentrum 

0101 OSLO

Norway

 

 

Tel.: +47 815 70 477

E-mail: ncu@kreftforeningen.no

 

Contact person: Janina Lassila 

Mobile: +47 900 323 97

 

For individual medical questions we encourage you to contact the NCU member league in your country.